Table 1. Patient and tumour characteristics of 340 breast cancer samples divided according to ERβ1 status and for all patients.
| Clinicopathological variables | All patients | ERβ1 positive | ERβ1 negative |
|---|---|---|---|
|
Characteristics | |||
| Number | 340 | 241 (76.3)a | 75 (23.7)a |
| Age (years)b | 58 (23–86) | 58 (23–86) | 58 (32–82) |
| Tumour diameter (mm)b |
15 (1–73) |
15 (1–73) |
15 (4–50) |
|
T stage (mm) | |||
| T1 (⩽20) | 224 (66.5) | 155 (65.1) | 54 (72.0) |
| T2 (21–50) | 103 (30.6) | 75 (31.5) | 19 (25.3) |
| T3 (>50) | 10 (3.0) | 8 (3.4) | 2 (2.7) |
| Missing |
3 |
3 |
0 |
|
Histological type | |||
| Ductal | 264 (78.6) | 181 (76.4) | 62 (82.6) |
| Lobular | 57 (16.9) | 45 (19.0) | 9 (12.0) |
| Mixed | 9 (2.7) | 6 (2.5) | 3 (4.0) |
| Other | 6 (1.8) | 5 (2.1) | 1 (1.3) |
| Missing |
4 |
4 |
0 |
|
ERα staus | |||
| Positive | 258 (80.1) | 197 (82.4) | 52 (71.2) |
| Negative | 64 (19.1) | 42 (17.6) | 21 (28.8) |
| Missing |
18 |
3 |
2 |
|
ERβcx staus | |||
| Positive | 279 (88.6) | 210 (90.1) | 58 (81.7) |
| Negative | 36 (11.4) | 23 (9.9) | 13 (18.3) |
| Missing |
25 |
8 |
4 |
|
PR status | |||
| Positive | 249 (73.9) | 182 (76.2) | 49 (66.2) |
| Negative | 88 (26.1) | 57 (23.8) | 25 (33.8) |
| Missing |
3 |
3 |
1 |
|
Elston histological grading | |||
| 1 | 89 (26.4) | 60 (25.2) | 22 (29.3) |
| 2 | 171 (50.7) | 126 (52.9) | 37 (49.3) |
| 3 | 77 (22.9) | 52 (21.8) | 16 (21.3) |
| Missing |
3 |
3 |
0 |
|
Proliferation | |||
| Low | 221 (66.4) | 159 (67.4) | 47 (64.4) |
| High | 112 (33.6) | 77 (32.6) | 26 (35.6) |
| Missing |
7 |
236 |
2 |
|
Sentinel lymph node status | |||
| N0 | 195 (57.4) | 134 (55.6) | 46 (61.3) |
| N1 |
145 (42.6) |
107 (44.4) |
29 (38.7) |
|
Adjuvant treatment | |||
| Chemotherapy | 132 (39.8) | 95 (39.4) | 30 (40.0) |
| Radiotherapy | 250 (75.3) | 182 (77.4) | 52 (71.2) |
| All endocrine treatment | 268 (80.7) | 195 (83.0) | 55 (75.3) |
| Oestrogen receptor antagonist | 152 (44.7) | 110 (45.6) | 29 (38.7) |
| Aromatase inhibitor | 63 (18.5) | 40 (16.6) | 20 (26.7) |
| Combined endocrine treatment |
53 (15.6) |
45 (18.6) |
6 (8.0) |
|
ERα/PR status | |||
| Positive/positive | 207 (67.0) | 165 (69.6) | 42 (58.3) |
| Positive/negative | 40 (12.9) | 31 (13.1) | 9 (12.5) |
| Negative/positive | 21 (6.8) | 15 (6.3) | 6 (8.3) |
| Negative/negative | 41 (13.3) | 26 (11.0) | 15 (20.8) |
| Missing |
31 |
4 |
3 |
|
ERα/PR statusc |
All patientsc |
ERβcx positive |
ERβcx negative |
| Positive/positive | 208 (67.5) | 186 (68.1) | 22 (62.9) |
| Positive/negative | 39 (12.7) | 37 (13.6) | 2 (5.7) |
| Negative/positive | 22 (7.1) | 19 (7.0) | 3 (8.6) |
| Negative/negative | 39 (12.7) | 31 (11.4) | 8 (22.9) |
| Missing | 32 | 6 | 1 |
Abbreviations: ER=oestrogen receptor; PR=progesterone receptor. Data were collected from patient medical records, except for ERα, ERβ1 and ERβcx, which were evaluated within this study using immunohistochemistry. All numbers are cases (%) if not stated otherwise.
a
Twenty-four patients had missing ERβ1 classification.
b
Median (range).
c
Note that data presented below is on ERβcx expression.